SAN ANTONIO — The addition of carboplatin to a standard neoadjuvant chemotherapy regimen significantly improves disease-free or event-free survival in patients with early-stage triple-negative breast ...
Outcomes of neoadjuvant combination chemotherapy with and without targeted therapy in HER2-positive breast cancer: A real-world experience from tertiary care center in North India. This is an ASCO ...
Data from patients treated with neoadjuvant PTCH between January 2015 and December 2024 were retrospectively reviewed. The primary end point was the pathologic complete response (pCR) rate, with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results